Tumor mutational burden and immune signatures interplay in renal cell carcinoma

Affiliations

Editorial

Evgeny Yakirevich et al. Ann Transl Med. 2020 Mar.

. 2020 Mar;8(6):269.

doi: 10.21037/atm.2020.02.81.

¹ Department of Pathology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
Zhang C, Li Z, Qi F, Hu X, Luo J. Zhang C, et al. Ann Transl Med. 2019 Nov;7(22):648. doi: 10.21037/atm.2019.10.84. Ann Transl Med. 2019. PMID: 31930049 Free PMC article.

1. Aggen DH, Drake CG, Rini BI. Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer - Combination Therapy in the First Line Setting. Clin Cancer Res 2020. [Epub ahead of print]. 10.1158/1078-0432.CCR-19-3323 - DOI - PubMed
1. Zhang C, Li Z, Qi F, et al. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma. Ann Transl Med 2019;7:648. 10.21037/atm.2019.10.84 - DOI - PMC - PubMed
1. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-21. 10.1038/nature12477 - DOI - PMC - PubMed
1. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017;9:34. 10.1186/s13073-017-0424-2 - DOI - PMC - PubMed
1. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-8. 10.1038/nature12213 - DOI - PMC - PubMed